178 related articles for article (PubMed ID: 37900570)
21. Dronedarone for the treatment of atrial fibrillation with concomitant heart failure with preserved and mildly reduced ejection fraction: a post-hoc analysis of the ATHENA trial.
Vaduganathan M; Piccini JP; Camm AJ; Crijns HJGM; Anker SD; Butler J; Stewart J; Braceras R; Albuquerque APA; Wieloch M; Hohnloser SH
Eur J Heart Fail; 2022 Jun; 24(6):1094-1101. PubMed ID: 35293087
[TBL] [Abstract][Full Text] [Related]
22. Five-year mortality of heart failure with preserved, mildly reduced, and reduced ejection fraction in a 4880 Chinese cohort.
Chen S; Huang Z; Liang Y; Zhao X; Aobuliksimu X; Wang B; He Y; Kang Y; Huang H; Li Q; Yao Y; Lu X; Qian X; Xie X; Liu J; Liu Y
ESC Heart Fail; 2022 Aug; 9(4):2336-2347. PubMed ID: 35437939
[TBL] [Abstract][Full Text] [Related]
23. Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials.
Täger T; Atar D; Agewall S; Katus HA; Grundtvig M; Cleland JGF; Clark AL; Fröhlich H; Frankenstein L
Heart Fail Rev; 2021 Nov; 26(6):1421-1435. PubMed ID: 32314085
[TBL] [Abstract][Full Text] [Related]
24. Comparing benefits from sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in randomized clinical trials: a network meta-analysis.
Sabouret P; Bocchino PP; Angelini F; D'Ascenzo F; Galati G; Fysekidis M; DE Ferrari GM; Fischman DL; Bhatt DL; Biondi-Zoccai G
Minerva Cardiol Angiol; 2023 Apr; 71(2):199-207. PubMed ID: 35195376
[TBL] [Abstract][Full Text] [Related]
25. Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction.
Myhre PL; Vaduganathan M; Claggett BL; Miao ZM; Jhund PS; de Boer RA; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Martinez F; Shah SJ; Desai AS; Lindholm D; Petersson M; Langkilde AM; McMurray JJV; Solomon SD
JACC Heart Fail; 2022 Dec; 10(12):902-913. PubMed ID: 36114137
[TBL] [Abstract][Full Text] [Related]
26. Empagliflozin: A Review in Symptomatic Chronic Heart Failure.
Frampton JE
Drugs; 2022 Nov; 82(16):1591-1602. PubMed ID: 36374374
[TBL] [Abstract][Full Text] [Related]
27. Lessons from a pre-specified meta-analysis of sodium-glucose cotransporter-2 (SGLT2) inhibitors in heart failure: Time for new clinical recommendations.
Kotit S
Glob Cardiol Sci Pract; 2023 May; 2023(2):e202314. PubMed ID: 37351098
[TBL] [Abstract][Full Text] [Related]
28. Beneficial Effects of Dipeptidyl Peptidase-4 Inhibitors on Heart Failure With Preserved Ejection Fraction and Diabetes.
Enzan N; Matsushima S; Kaku H; Tohyama T; Nagata T; Ide T; Tsutsui H
JACC Asia; 2023 Feb; 3(1):93-104. PubMed ID: 36873765
[TBL] [Abstract][Full Text] [Related]
29. Empagliflozin in Heart Failure With Predicted Preserved Versus Reduced Ejection Fraction: Data From the EMPA-REG OUTCOME Trial.
Savarese G; Uijl A; Lund LH; Anker SD; Asselbergs F; Fitchett D; Inzucchi SE; Koudstaal S; Ofstad AP; Schrage B; Vedin O; Wanner C; Zannad F; Zwiener I; Butler J
J Card Fail; 2021 Aug; 27(8):888-895. PubMed ID: 34364665
[TBL] [Abstract][Full Text] [Related]
30. Cardiovascular effects of non-insulin glucose-lowering agents: a comprehensive review of trial evidence and potential cardioprotective mechanisms.
Savarese G; Butler J; Lund LH; Bhatt DL; Anker SD
Cardiovasc Res; 2022 Jul; 118(10):2231-2252. PubMed ID: 34390570
[TBL] [Abstract][Full Text] [Related]
31. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis.
Li HL; Lip GYH; Feng Q; Fei Y; Tse YK; Wu MZ; Ren QW; Tse HF; Cheung BY; Yiu KH
Cardiovasc Diabetol; 2021 May; 20(1):100. PubMed ID: 33962654
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of spironolactone in the heart failure with mid-range ejection fraction and heart failure with preserved ejection fraction: A meta-analysis of randomized clinical trials.
Xiang Y; Shi W; Li Z; Yang Y; Wang SY; Xiang R; Feng P; Wen L; Huang W
Medicine (Baltimore); 2019 Mar; 98(13):e14967. PubMed ID: 30921200
[TBL] [Abstract][Full Text] [Related]
33. Safety outcomes of SGLT2i in the heart failure trials: A systematic review and Meta-analysis.
Younes AM; Salem M; Maraey A; Nomigolzar S; Sewell K; Khalil M; Elzanaty A; Saeyeldin A; Dar M
Int J Cardiol; 2022 Nov; 366():51-56. PubMed ID: 35777490
[TBL] [Abstract][Full Text] [Related]
34. Exercise-based rehabilitation for heart failure.
Taylor RS; Sagar VA; Davies EJ; Briscoe S; Coats AJ; Dalal H; Lough F; Rees K; Singh S
Cochrane Database Syst Rev; 2014 Apr; 2014(4):CD003331. PubMed ID: 24771460
[TBL] [Abstract][Full Text] [Related]
35. Sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction: A protocol for meta-analysis.
Fukuta H; Hagiwara H; Kamiya T
Medicine (Baltimore); 2021 Dec; 100(51):e28448. PubMed ID: 34941199
[TBL] [Abstract][Full Text] [Related]
36. Sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials.
Fukuta H; Hagiwara H; Kamiya T
Int J Cardiol Heart Vasc; 2022 Oct; 42():101103. PubMed ID: 36032269
[TBL] [Abstract][Full Text] [Related]
37. Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-Systematic review and meta-analysis of randomized placebo-controlled trials.
Salah HM; Al'Aref SJ; Khan MS; Al-Hawwas M; Vallurupalli S; Mehta JL; Mounsey JP; Greene SJ; McGuire DK; Lopes RD; Fudim M
Am Heart J; 2021 Feb; 232():10-22. PubMed ID: 33214130
[TBL] [Abstract][Full Text] [Related]
38. Effect of pharmacological treatment on outcomes of heart failure with preserved ejection fraction: an updated systematic review and network meta-analysis of randomized controlled trials.
Lin Y; Cai Z; Yuan J; Liu H; Pang X; Chen Q; Tang X; Geng Q; Dong S
Cardiovasc Diabetol; 2022 Nov; 21(1):237. PubMed ID: 36348348
[TBL] [Abstract][Full Text] [Related]
39. The prognosis of mid-range ejection fraction heart failure: a systematic review and meta-analysis.
Altaie S; Khalife W
ESC Heart Fail; 2018 Dec; 5(6):1008-1016. PubMed ID: 30211480
[TBL] [Abstract][Full Text] [Related]
40. Benefit of sodium-glucose cotransporter-2 inhibitors on survival outcome is related to the type of heart failure: A meta-analysis.
Zhao L; Guo W; Huang W; Wang L; Huang S
Diabetes Res Clin Pract; 2022 May; 187():109871. PubMed ID: 35413392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
